Takeda Pharmaceutical Company Limited and Ligand Pharmaceuticals Incorporated: A Detailed Gross Profit Analysis

Pharmaceutical Giants: A Decade of Gross Profit Insights

__timestampLigand Pharmaceuticals IncorporatedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014554020001256834000000
Thursday, January 1, 2015661070001271973000000
Friday, January 1, 20161034020001173296000000
Sunday, January 1, 20171357360001274610000000
Monday, January 1, 20182451160001437534000000
Tuesday, January 1, 20191089350002201424000000
Wednesday, January 1, 20201560000002203504000000
Friday, January 1, 20212149570002462160000000
Saturday, January 1, 20221434180002783406000000
Sunday, January 1, 2023962650002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Cracking the code

A Tale of Two Pharmaceuticals: Gross Profit Trends from 2014 to 2023

In the competitive world of pharmaceuticals, understanding financial performance is crucial. This analysis delves into the gross profit trends of Takeda Pharmaceutical Company Limited and Ligand Pharmaceuticals Incorporated over the past decade. Takeda, a global leader, consistently outperformed with a staggering 1,975% higher average gross profit compared to Ligand. From 2014 to 2023, Takeda's gross profit surged by approximately 125%, peaking in 2023. Meanwhile, Ligand experienced a more volatile journey, with a notable peak in 2018, achieving a 343% increase from its 2014 figures. However, by 2023, Ligand's profits dipped by 61% from its 2018 high. This data highlights the resilience and growth trajectory of Takeda, while Ligand's fluctuations suggest a more dynamic market strategy. Missing data for 2024 indicates potential shifts in the industry landscape, warranting close observation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025